Brain tumor patients may get a survival boost from targeted drug combo

NCT ID NCT03212742

Ongoing Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olaparib, then checking if the combination helps patients live longer. About 91 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (a PARP inhibitor) combined with temozolomide chemotherapy and radiation therapy
What this could lead to: If successful, this combination could extend survival for patients with aggressive brain tumors that cannot be surgically removed.
What could go wrong: This is an early-phase trial (Phase I/IIa) with a small number of participants, so results may not apply broadly. The added drug may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT GLIOMAS PARP INHIBITOR RADIOTHERAPY

Contacts and locations

Locations

CH du Havre

Le Havre, France
CHU

Amiens, France
CHU

Bordeaux, France
Centre Eugène Marquis

Rennes, France
Centre François Baclesse

Caen, 14076, France
Centre Guillaume le Conquérant

Le Havre, France
Centre Henri Becquerel

Rouen, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, France
Centre léon Bérard

Lyon, France
GHBS

Lorient, France
Hôpitaux universitaires La Pitié Salpétrière - Charles Foix

Paris, France
Institut Claudius Regaud

Toulouse, France
Institut Curie

Paris, France
Institut de Cancérologie de l'Ouest

Angers, France
Institut de Cancérologie de l'Ouest

Saint-Herblain, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.